A First-in-Human Study of QY211 Gel in Adult Subjects

NCT05843422 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: 0.1% QY211 Gel or placebo
DRUG: 0.3% QY211 Gel or placebo
DRUG: 0.8% QY211 Gel or placebo
DRUG: 1.5% QY211 Gel or placebo

Sponsor

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.